Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc (NY: CYBN )

10.38 +0.13 (+1.27%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
38 39 Next >
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
Via Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 20, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.69% at $0.16 LOSERS: 
Via Benzinga
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be... 
Via Benzinga
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.57% at $0.33 
Via Benzinga
EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics
If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelic Stock Gainers And Losers From April 18, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.66% at $0.28 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From April 14, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From April 13, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.41% at $0.24 
Via Benzinga
Cybin's (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
Via Investor Brand Network
Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics
CYB004 is one of Cybin’s (NYSE: CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and ... 
Via Benzinga
Why Psychedelics Could Soon Replace Antidepressants
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults... 
Via FinancialNewsMedia
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 11, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.52% at $0.17 
Via Benzinga
Performance Comparisons Of The 5 Cannabis Sector Categories
Here is a summary of how each of the 5 categories in the cannabis sector performed over four time periods, to highlight the different category trends that are underway. 
Via Talk Markets
Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.54% at $0.16 
Via Benzinga
WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies
Cybin Inc. (NYSE: CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent ... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position Of Psychedelic Programs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position of Psychedelic Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space
Via Investor Brand Network
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.